Gert Huppertz‐Hauss

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease

Aida Kapic Lunder, Johannes R. Hov, Arne Borthne et al. · Gastroenterology · 2016 · 215 citations · Full text

Medicine, Internal Medicine, Radiology +10

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton et al. · Journal of Internal Medicine · 2019 · 122 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population

Svein Oskar Frigstad, Marte Lie Høivik, Jørgen Jahnsen et al. · Scandinavian Journal of Gastroenterology · 2016 · 103 citations · Full text

Medicine, Nutrition, Nutritional Sciences +14

Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study

Gert Huppertz‐Hauss, Marte Lie Høivik, Lars‐Petter Jelsness‐Jørgensen et al. · Scandinavian Journal of Gastroenterology · 2016 · 84 citations

Medicine, Internal Medicine, Clinical Epidemiology +11